Glutamic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanism

Vaccine

Volumn 28, Issue 24, 2010, Pages 4052-4058

  Gong, Zhaohui ^a   Pan, Lin ^a   Le, Yanping ^a   Liu, Qiong ^a   Zhou, Mi ^a   Xing, Wenhua ^a   Zhuo, Renjie ^a   Wang, Shaomin ^a   Guo, Junming ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Autoimmune diabetes; Epitope; Glutamic acid decarboxylase

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA TOXIN B SUBUNIT GLUTAMATE DECARBOXYLASE 65 PEPTIDE[351-545]; GAMMA INTERFERON; GANGLIOSIDE GM1; GLUTAMATE DECARBOXYLASE 65 PEPTIDE[351-545]; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH2 CELL;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; AUTOANTIGENS; CHOLERA TOXIN; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNOMODULATION; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; RECOMBINANT FUSION PROTEINS; TH2 CELLS;

EID: 77952582056     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.005     Document Type: Article

References (50)

1. Garside P., and Mowat A.M. Oral tolerance. Semin Immunol 13 (2001) 177-185
2. Polanski M., Melican N.S., Zhang J., and Weiner H.L. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 10 (1997) 339-346
3. Song H.Y., Abad M.M., Mahoney C.P., and McEvoy R.C. Human insulin B chain but not A chain decreases the rate of diabetes in BB rats. Diabetes Res Clin Pract 46 (1999) 109-114
4. Ramiya V.K., Shang X.Z., Pharis P.G., Wasserfall C.H., Stabler T.V., Muir A.B., et al. Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun 9 (1996) 349-356
5. Ramiya V.K., and Maclaren N.K. Insulin in diabetes prevention. Horm Res 48S (1997) 67-70
6. Bergerot I., Ploix C., Petersen J., Moulin V., Rask C., Fabien N., et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 94 (1997) 4610-4614
7. Arakawa T., Chong D.K., Merritt J.L., and Langridge W.H. Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res 6 (1997) 403-413
8. Ploix C., Bergerot I., Durand A., Czerkinsky C., Holmgren J., and Thivolet C. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 48 (1999) 2150-2156
9. Arakawa T., Yu J., Chong D.K., Hough J., Engen P.C., and Langridge W.H. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16 (1998) 934-938
10. Gong Z., Jin Y., and Zhang Y. Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J Biotechnol 119 (2005) 93-105
11. Atkinson M.A., and MacLaren N.K. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331 (1994) 1428-1436
12. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183 (1996) 1561-1567
13. Ogino T., Sato K., Miyokawa N., Kimura S., and Katagiri M. Importance of GAD65 peptides and I-Ag7 in the development of insulitis in nonobese diabetic mice. Immunogenetics 51 (2000) 538-545
14. Quinn A., McInerney B., Reich E.P., Kim O., Jensen K.P., and Sercarz E.E. Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct V beta genes. J Immunol 166 (2001) 2982-2991
15. Kaufman D.L., Clare-Salzler M., Tian J., Forsthuber T., Ting G.S., Robinson P., et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366 (1993) 69-72
16. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., and McDevitt H.O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366 (1993) 72-75
17. Gong Z., Long X., Pan L., Le Y., Liu Q., Wang S., et al. Cloning, expression, purification and characterization of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion protein in Escherichia coli. Protein Expr Purif 66 (2009) 191-197
18. Sun J.B., Holmgren J., and Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 91 (1994) 10795-10799
19. Gong Z., Jin Y., and Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine expressed in silkworm. Vaccine 25 (2007) 1444-1451
20. Zhang Z.J., Davidson L., Eisenbarth G., and Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88 (1991) 10252-10256
21. Ma S.W., Zhao D.L., Yin Z.Q., Mukherjee R., Singh B., Qin H.Y., et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 3 (1997) 793-796
22. Faria A.M., and Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 13 (2006) 143-157
23. Tisch R., Wang B., and Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 163 (1999) 1178-1187
24. Kumar V., Maglione J., Thatte J., Pederson B., Sercarz E., and Ward E.S. Induction of a type 1 regulatory CD4 T cell response following V beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int Immunol 13 (2001) 835-841
25. Jin L., Zhu A., Wang Y., Chen Q., Xiong Q., Li J., et al. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol 180 (2008) 58-63
26. Chen S.L., Whiteley P.J., Freed D.C., Rothbard J.B., Peterson L.B., and Wicker L.S. Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide. J Autoimmun 7 (1994) 635-641
27. Tian J., Clare-Salzler M., Herschenfeld A., Middleton B., Newman D., Mueller R., et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2 (1996) 1348-1353
28. Jun H.S., Chung Y.H., Han J., Kim A., Yoo S.S., Sherwin R.S., et al. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 45 (2002) 668-676
29. Im J.S., Quinn A., Sercarz E.E., and Lake D.F. Molecular profile of the T cell receptors of regulatory and effector CD4+ T cells recognizing overlapping determinants on glutamic acid decarboxylase (524-543). Mol Immunol 40 (2004) 971-980
30. Han G., Li Y., Wang J., Wang R., Chen G., Song L., et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD (500-585). J Immunol 174 (2005) 4516-4524
31. Gebe J.A., Falk B., Unrath K., and Nepom G.T. Autoreactive T cells in a partially humanized murine model of T1D. Ann NY Acad Sci 1103 (2007) 69-76
32. Gebe J.A., Unrath K.A., Yue B.B., Miyake T., Falk B.A., and Nepom G.T. Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. J Autoimmun 30 (2008) 197-206
33. Wang B., and Tisch R. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunol Res 42 (2008) 246-258
34. Elagin R.B., Balijepalli S., Diacovo M.J., Baekkeskov S., and Jaume J.C. Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice. J Autoimmun 33 (2009) 50-57
35. Aspord C., and Thivolet C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 130 (2002) 204-211
36. Harrison L.C., Dempsey-Collier M., Kramer D.R., and Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 184 (1996) 2167-2174
37. Hänninen A., and Harrison L.C. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 173 (2000) 109-119
38. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmér M., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19 (2005) 238-246
39. Raz I., Elias D., Avron A., Tamir M., Metzger M., and Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
40. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
41. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598-2608
42. Schatz D.A., and Bingley P.J. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 14 Suppl. 1 (2001) 619-622
43. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28 (2005) 1068-1076
44. Pozzilli P., Pitocco D., Visalli N., Cavallo M.G., Buzzetti R., Crinò A., et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43 (2000) 1000-1004
45. Barker J.M., McFann K.K., and Orban T. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 50 (2007) 1603-1606
46. Ergun-Longmire B., Marker J., Zeidler A., Rapaport R., Raskin P., Bode B., et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 1029 (2004) 260-277
47. Cockey C.D. Oral insulin doesn't prevent type 1 diabetes. AWHONN Lifelines 7 (2003) 310-311
48. Hanninen A., and Harrison L.C. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?. Rev Diabet Stud 1 (2004) 113-121
49. Bresson D., and von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?. Autoimmun Rev 6 (2007) 315-322
50. Ilan Y. Oral tolerance: can we make it work?. Hum Immunol 70 (2009) 768-776